Welcome to the September 2023 edition of our Monthly Insight Series. This month we are giving a quick overview of the various reports we’ve released to our clients this summer—it’s been a busy one!
Read MoreWelcome to the August 2023 edition of our Monthly Insight Series. This month we take a deeper look into independent community oncology practices’ evolving interest in joining oncology network aggregators.
Taylor CrutisonCMMI has launched its new oncology pilot, the Enhancing Oncology Model, sparking questions about its new features vs the Oncology Care Model, the benefits and concerns for participating practices, and CMMI’s ability to successfully implement the program.
Taylor CrutisonWelcome to the July 2023 edition of our Monthly Insights Series. This month we want to share some more thoughts on opportunities for manufacturer engagement with IDN stakeholders—the IDN pharmacy/pharmacists, in particular.
Cindy ChenAs more providers explore clinical pathways as a tool for increasing clinical consistency and quality, we need to examine adoption benefits and challenges, provider compliance, and potential access risks for manufacturers.
Lee BlansettWelcome to the May 2023 edition of our Monthly Insight Series. This month we are examining how Payers’ oncology pathways sometimes conflict with their own coverage policies, and how they can differ but still be aligned from a Payer perspective.
Chris Van DenburgChanges to Medicare, including Medicare Advantage, have important repercussions on patient access to care, oncologists’ treatment decisions, and drug manufacturers’ processes.
Lee BlansettWelcome to the April 2023 edition of our Monthly Insight Series. This month we are evaluating the desire among oncology pharmacists to return to in-person meetings.
Cindy ChenWelcome to the March 2023 edition of our Monthly Insight Series. This month we discuss how Humana terminated its employer group line of business and the implications.
Chris Van DenburgWe want to give you a look at some of the topics we’re planning to explore this year, as we enter yet another period of rapid change, upheaval, and uncertainty in 2023-2025.
Lee BlansettWelcome to the February 2023 edition of our Monthly Insight Series. This month we discuss how community oncology providers are engaging in value-based care.
Taylor Crutison, Lee BlansettWelcome to the January 2023 edition of our Monthly Insight Series. This month we discuss value-based care in oncology from a private-payer perspective.
Chris Van Denburg, Lee BlansettWelcome to the December 2022 edition of our Monthly Insight Series. This month we highlight the Inflation Reduction Act of 2022 (IRA).
Taylor Crutison, Cindy Chen, Lee BlansettWelcome to the October 2022 edition of our Monthly Insight Series. This month we discuss our new Perspectives on Vertical Payers report.
Chris Van DenburgWelcome to the September 2022 edition of our Monthly Insight Series. This month we discuss our inaugural Payer Report Series, which is launching soon.
Chris Van DenburgWelcome to the June 2022 edition of our Monthly Insight Series. This month we highlight several queries that have generated lively discussions thus far.
Cindy ChenWelcome to the May edition of our Monthly Insight Series. MAI conducts a Brand Survey as part of our annual IDN Trend Survey. For 2022, we continued this tradition as we set out to understand the prescribing burden for IDN oncologists.
Cindy ChenAs we busily analyze field data collected from our annual IDN survey, we would like to offer a sneak peek at how oncology pharmacists want to engage with manufacturers in 2022 and beyond.
Cindy ChenWelcome to the March edition of our Monthly Insight Series. This month we review several highlights from our December 2021 Special Topic Report on Payers.
Chris Van Denburg